Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Fukuda T et al. | Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. | 1991 | Int. Arch. Allergy Appl. Immunol. | pmid:1718889 |
Murase N et al. | FK 506 prevents spontaneous diabetes in the BB rat. | 1991 | Transplant. Proc. | pmid:1703705 |
Meiser BM et al. | Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. | 1991 | Lancet | pmid:1719321 |
Watanabe K et al. | Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. | 1991 | Transplant. Proc. | pmid:1703706 |
Jorgensen WL | Rusting of the lock and key model for protein-ligand binding. | 1991 | Science | pmid:1719636 |
Kobayashi N et al. | Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. | 1991 | Transplant. Proc. | pmid:1703707 |
Keenan RJ et al. | Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. | 1991 | Transplantation | pmid:1719668 |
Strasser S et al. | The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. | 1991 | Transplant. Proc. | pmid:1703709 |
McMichael J et al. | Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721275 |
Ali Shah I et al. | Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. | 1991 | Transplant. Proc. | pmid:1721276 |
Moochhala SM et al. | Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721277 |
Sumpio BE and Phan S | Nephrotoxic potential of FK 506. | 1991 | Transplant. Proc. | pmid:1721278 |
Katz HR et al. | Mast cell biochemical and functional heterogeneity. | 1991 | Transplant. Proc. | pmid:1721308 |
de Paulis A et al. | Antiinflammatory effect of FK 506 on human basophils. | 1991 | Transplant. Proc. | pmid:1721309 |
Su MS and Semerjian A | Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. | 1991 | Transplant. Proc. | pmid:1721310 |
Andersson J et al. | The effects of FK 506 on cytokine production are dependent on the mode of cell activation. | 1991 | Transplant. Proc. | pmid:1721311 |
Rucay P et al. | FK 506 rescue therapy for refractory acute rejection in five liver recipients. | 1991 | Transplant. Proc. | pmid:1721340 |
Macleod AM and Thomson AW | FK 506: an immunosuppressant for the 1990s? | 1991 | Lancet | pmid:1702172 |
Reding R et al. | Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. | 1991 | Transplant. Proc. | pmid:1721341 |
Uemoto S et al. | Experience with FK 506 in living related donor liver transplantation. | 1991 | Transplant. Proc. | pmid:1721342 |
Fung JJ et al. | Adverse effects associated with the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721372 |
Omar G et al. | FK 506 inhibition of cyclosporine metabolism by human liver microsomes. | 1991 | Transplant. Proc. | pmid:1703356 |
Hebert MF et al. | Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721373 |
Eiras G et al. | Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. | 1991 | Transplant. Proc. | pmid:1703357 |
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721374 | |
Christians U et al. | Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. | 1991 | Transplant. Proc. | pmid:1703358 |
Morris SM et al. | Disruption of renal function and gene expression by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721375 |
Lagodziński Z et al. | Effect of FK 506 on B-cell responses. | 1991 | Transplant. Proc. | pmid:1703359 |
Jacobs TW et al. | The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. | 1991 | Transplant. Proc. | pmid:1721403 |
Abu-Elmagd KM et al. | Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721404 |
Adams CK and Famili P | A study of the effects of the drug FK 506 on gingival tissues. | 1991 | Transplant. Proc. | pmid:1721405 |
Pirsch JD et al. | Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721406 |
de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
Griffiths EJ and Halestrap AP | Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. | 1991 | Biochem. J. | pmid:1706598 |
Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
Wada H et al. | An attempt to induce tolerance to skin grafts in congenic mice with FK 506. | 1991 | Transplant. Proc. | pmid:1721435 |
Kuroki H et al. | Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. | 1991 | Transplant. Proc. | pmid:1721436 |
Ito T et al. | Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. | 1991 | Transplant. Proc. | pmid:1721437 |
McAlpine JB et al. | Revised NMR assignments for rapamycin. | 1991 | J. Antibiot. | pmid:1712766 |
Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
Morris PJ | Cyclosporine, FK-506 and other drugs in organ transplantation. | 1991 | Curr. Opin. Immunol. | pmid:1721824 |
Lhoëst G et al. | Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. | 1991 | Pharm Acta Helv | pmid:1722046 |
Nicoletti F et al. | FK-506 prevents diabetes in diabetes-prone BB/Wor rats. | 1991 | Int. J. Immunopharmacol. | pmid:1722192 |
Starzl TE et al. | [Clinical experience with FK 506]. | 1991 | Presse Med | pmid:1722311 |
Nakahama H et al. | Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. | 1991 | J. Cardiovasc. Pharmacol. | pmid:1725322 |
Romanowski P et al. | [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. | 1991 | Postepy Biochem. | pmid:1725924 |
Altmeyer A et al. | Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. | 1991 | Int. J. Immunopharmacol. | pmid:1726093 |
Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |